Finding New Uses for Existing Drugs Through Computational Drug Repositioning
Author Information
Author(s): Li Yvonne Y., Jianghong Jones, Steven J. M., Bourne Philip E.
Primary Institution: Canada's Michael Smith Genome Sciences Centre, British Columbia Cancer Agency
Hypothesis
Can a computational drug repositioning pipeline effectively identify novel drug-target interactions?
Conclusion
The study successfully identified nilotinib as a potent MAPK14 inhibitor, suggesting its potential use in treating inflammatory diseases.
Supporting Evidence
- Nilotinib was validated as a potent MAPK14 inhibitor with an IC50 of 40 nM.
- 31 of the top predicted interactions were supported by published literature.
- The computational method enriched predicted drug-target interactions with known interactions up to 20 times.
Takeaway
Researchers used a computer program to find new ways to use old medicines, and they discovered that a cancer drug could help with inflammation.
Methodology
The study developed a computational pipeline for large-scale molecular docking of small molecule drugs against protein drug targets to predict novel interactions.
Potential Biases
The reliance on known interactions for scoring may introduce bias in predicting novel interactions.
Limitations
The method may have high false positive rates and does not account for water and cofactor molecules during simulations.
Statistical Information
P-Value
40 nM
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website